Atossa Therapeutics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more
Atossa Therapeutics Inc (YAG2) - Total Assets
Latest total assets as of September 2025: €58.01 Million EUR
Based on the latest financial reports, Atossa Therapeutics Inc (YAG2) holds total assets worth €58.01 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Atossa Therapeutics Inc - Total Assets Trend (2016–2024)
This chart illustrates how Atossa Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Atossa Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Atossa Therapeutics Inc's total assets of €58.01 Million consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 93.0% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Atossa Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atossa Therapeutics Inc's current assets represent 97.4% of total assets in 2024, an increase from 78.5% in 2016.
- Cash Position: Cash and equivalents constituted 93.0% of total assets in 2024, up from 73.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Atossa Therapeutics Inc Competitors by Total Assets
Key competitors of Atossa Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Atossa Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Atossa Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Atossa Therapeutics Inc is currently not profitable relative to its asset base.
Atossa Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.77 | 13.30 | 7.23 |
| Quick Ratio | 6.77 | 13.30 | 7.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €47.45 Million | € 71.31 Million | € 9.75 Million |
Atossa Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Atossa Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.00 |
| Latest Market Cap to Assets Ratio | 1.16 |
| Asset Growth Rate (YoY) | -20.6% |
| Total Assets | €76.44 Million |
| Market Capitalization | $88.44 Million USD |
Valuation Analysis
Above Book Valuation: The market values Atossa Therapeutics Inc's assets above their book value (1.16 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Atossa Therapeutics Inc's assets decreased by 20.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Atossa Therapeutics Inc (2016–2024)
The table below shows the annual total assets of Atossa Therapeutics Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €76.44 Million | -20.58% |
| 2023-12-31 | €96.25 Million | -22.08% |
| 2022-12-31 | €123.53 Million | -12.55% |
| 2021-12-31 | €141.26 Million | +229.75% |
| 2020-12-31 | €42.84 Million | +195.65% |
| 2019-12-31 | €14.49 Million | +23.63% |
| 2018-12-31 | €11.72 Million | +43.56% |
| 2017-12-31 | €8.16 Million | +96.99% |
| 2016-12-31 | €4.14 Million | -- |